Pharma News

U.S. Food and Drug Administration officially approved a Biologics License Application (BLA) for AVANCE, a processed human nerve scaffold developed by Axogen, for treating peripheral nerve discontinuities in both adults and pediatric patients, including infants aged as young as one month.

Rentschler Biopharma, a leading global contract development and manufacturing organization for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.

Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab), in a 300mg/2mL solution in a single-dose prefilled syringe for subcutaneous injection. In the U.S., OMLYCLO will be marketed and distributed exclusively by Celltrion USA, Inc.

Sun Pharmaceutical Industries Ltd. announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.

Sandoz the global leader in affordable medicines, today announced the European launch of Wyost® (denosumab 120 mg) and Jubbonti® (denosumab 60 mg).

Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity.

Cancer-fighting antibody drugs are designed to penetrate tumor cells and release a lethal payload deep within, but too often they don’t make it that far. A new study shows how this Trojan Horse strategy works better by exploiting calcium differences outside and inside cells.

Patients with diabetes have an increased risk of complications after stent implantation, according to a study from Karolinska Institutet in Sweden published in Diabetes Care. The study, which includes over 160,000 patients, emphasises the importance of tailoring treatment strategies for this specific patient group.